What exactly changed in the LLY analyst rating on March 18, 2026?

On March 18, 2026 UBS maintained a **Buy** rating on Eli Lilly (LLY). The firm reiterated a **$1,250** price target after strong Q4 results and upside guidance. The action was a reiteration, not an upgrade or downgrade.

How should investors interpret a maintained Buy in the LLY analyst rating?

A maintained Buy signals the analyst still sees upside versus risk. It confirms confidence in revenue and pipeline assumptions but is not a guaranteed outcome. Investors should combine the LLY analyst rating with their risk profile and financial goals.

Does the UBS note include a price target for LLY?

Yes. UBS kept a **$1,250** LLY price target in its March 18, 2026 note. That target guides UBS’s upside scenario and reflects expected revenue and margin improvement assumptions.

Where can I read the UBS coverage of the LLY analyst rating?

See the UBS note summary on StreetInsider and a related Investing.com report for coverage and context. [StreetInsider coverage](https://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+Rating+on+Eli+Lilly+%28LLY%29+Following+Strong+Q4%2C+Upside+Guidance/26181022.html) and [Investing.com](#)

Analyst Ratings

UBS Maintains Buy on Eli Lilly and Company (LLY) March 18, 2026

ByDanny Kontos March 19, 2026March 19, 2026

UBS maintained a Buy rating on Eli Lilly and Company (LLY) on March 18, 2026, marking the latest LLY analyst rating update. UBS reiterated the Buy after strong Q4 results and upside guidance, and kept a $1,250 price target, according to recent coverage. The market moved modestly, with the stock showing a 0.11% change, equal to $1.03. This note summarizes the UBS view, market reaction, historical analyst context, and what the LLY analyst rating means for investors.